一种识别无肌钙蛋白的极低风险急诊科患者策略的多地点验证

Nicklaus P. Ashburn MD, MS , Anna C. Snavely PhD , Akalya Villenthi MS , Tara Hashemian MS , Michael W. Supples MD, MPH , Simon A. Mahler MD, MS
{"title":"一种识别无肌钙蛋白的极低风险急诊科患者策略的多地点验证","authors":"Nicklaus P. Ashburn MD, MS ,&nbsp;Anna C. Snavely PhD ,&nbsp;Akalya Villenthi MS ,&nbsp;Tara Hashemian MS ,&nbsp;Michael W. Supples MD, MPH ,&nbsp;Simon A. Mahler MD, MS","doi":"10.1016/j.jacadv.2025.101913","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with chest pain who are very low risk, defined by a History, Electrocardiogram, Age, and Risk factors (HEAR) score ≤1, may not require troponin testing.</div></div><div><h3>Objectives</h3><div>The aim of this study was to determine whether troponin testing is needed in patients with HEAR scores ≤1 in a multisite U.S. cohort.</div></div><div><h3>Methods</h3><div>We conducted an observational cohort study using the Wake Forest Chest Pain Registry. Patients ≥18 years old with HEART Pathway assessments and high-sensitivity troponin testing were accrued from 5 U.S. emergency departments (November 1, 2020-July 7, 2022). HEAR scores were prospectively completed by the treating clinician for patients with no known coronary artery disease and a nonischemic electrocardiogram. The outcome was 30-day major adverse cardiovascular events (MACE) (death, myocardial infarction [MI], and revascularization). The proportion of patients with HEAR scores ≤1 with MACE within 30 days was determined, and test characteristics were calculated. The net reclassification improvement index for troponin testing among patients with HEAR scores ≤1 was determined.</div></div><div><h3>Results</h3><div>Among 9,105 patients, 17.2% (1,565/9,105) had a HEAR score ≤1. At 30 days, MACE occurred in 0.7% (11/1,565; 95% CI: 0.4-1.3), with 3 deaths, 8 MIs, and 1 revascularization. The sensitivity and negative predictive value for 30-day MACE in patients with a HEAR score ≤1 were 97.9% (95% CI: 96.2-98.9) and 99.3% (95% CI: 98.7-99.6). Troponin testing correctly reclassified 8 with death, MI, or revascularization. Troponin was elevated among 74 without MACE, yielding a nonsignificant net reclassification improvement index of 0.7% (95% CI: −0.4 to 1.8).</div></div><div><h3>Conclusions</h3><div>Patients with no known coronary artery disease, a nonischemic electrocardiogram, and a HEAR score ≤1 had a missed MACE rate &lt;1%. Troponin testing identified additional patients with MACE but did not significantly improve risk stratification accuracy.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 7","pages":"Article 101913"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multisite Validation of a Strategy to Identify Very Low Risk Emergency Department Patients Without Troponin\",\"authors\":\"Nicklaus P. Ashburn MD, MS ,&nbsp;Anna C. Snavely PhD ,&nbsp;Akalya Villenthi MS ,&nbsp;Tara Hashemian MS ,&nbsp;Michael W. Supples MD, MPH ,&nbsp;Simon A. Mahler MD, MS\",\"doi\":\"10.1016/j.jacadv.2025.101913\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Patients with chest pain who are very low risk, defined by a History, Electrocardiogram, Age, and Risk factors (HEAR) score ≤1, may not require troponin testing.</div></div><div><h3>Objectives</h3><div>The aim of this study was to determine whether troponin testing is needed in patients with HEAR scores ≤1 in a multisite U.S. cohort.</div></div><div><h3>Methods</h3><div>We conducted an observational cohort study using the Wake Forest Chest Pain Registry. Patients ≥18 years old with HEART Pathway assessments and high-sensitivity troponin testing were accrued from 5 U.S. emergency departments (November 1, 2020-July 7, 2022). HEAR scores were prospectively completed by the treating clinician for patients with no known coronary artery disease and a nonischemic electrocardiogram. The outcome was 30-day major adverse cardiovascular events (MACE) (death, myocardial infarction [MI], and revascularization). The proportion of patients with HEAR scores ≤1 with MACE within 30 days was determined, and test characteristics were calculated. The net reclassification improvement index for troponin testing among patients with HEAR scores ≤1 was determined.</div></div><div><h3>Results</h3><div>Among 9,105 patients, 17.2% (1,565/9,105) had a HEAR score ≤1. At 30 days, MACE occurred in 0.7% (11/1,565; 95% CI: 0.4-1.3), with 3 deaths, 8 MIs, and 1 revascularization. The sensitivity and negative predictive value for 30-day MACE in patients with a HEAR score ≤1 were 97.9% (95% CI: 96.2-98.9) and 99.3% (95% CI: 98.7-99.6). Troponin testing correctly reclassified 8 with death, MI, or revascularization. Troponin was elevated among 74 without MACE, yielding a nonsignificant net reclassification improvement index of 0.7% (95% CI: −0.4 to 1.8).</div></div><div><h3>Conclusions</h3><div>Patients with no known coronary artery disease, a nonischemic electrocardiogram, and a HEAR score ≤1 had a missed MACE rate &lt;1%. Troponin testing identified additional patients with MACE but did not significantly improve risk stratification accuracy.</div></div>\",\"PeriodicalId\":73527,\"journal\":{\"name\":\"JACC advances\",\"volume\":\"4 7\",\"pages\":\"Article 101913\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772963X25003333\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772963X25003333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:胸痛的低危患者(病史、心电图、年龄和危险因素(HEAR)评分≤1)可能不需要肌钙蛋白检测。目的:本研究的目的是确定在美国多地点队列中,听力评分≤1的患者是否需要肌钙蛋白检测。方法:我们使用Wake Forest胸痛登记处进行了一项观察性队列研究。≥18岁接受HEART Pathway评估和高灵敏度肌钙蛋白检测的患者来自美国5个急诊科(2020年11月1日- 2022年7月7日)。对于没有已知冠状动脉疾病和非缺血性心电图的患者,由治疗临床医生前瞻性地完成HEAR评分。结果为30天主要不良心血管事件(MACE)(死亡、心肌梗死(MI)和血运重建术)。确定30天内HEAR评分≤1的患者发生MACE的比例,并计算试验特征。确定HEAR评分≤1的患者肌钙蛋白检测的净重分类改善指数。结果9105例患者中,17.2%(1565 / 9105)患者的HEAR评分≤1。30 d时,MACE发生率为0.7% (11/ 1565;95% CI: 0.4-1.3), 3例死亡,8例心肌梗死,1例血运重建术。对于HEAR评分≤1的患者,30天MACE的敏感性为97.9% (95% CI: 96.2-98.9),阴性预测值为99.3% (95% CI: 98.7-99.6)。肌钙蛋白检测正确地将其与死亡、心肌梗死或血运重建术重新分类。在没有MACE的74例患者中,肌钙蛋白升高,净重分类改善指数为0.7% (95% CI: - 0.4至1.8)。结论无已知冠状动脉疾病、非缺血性心电图、HEAR评分≤1的患者MACE漏报率为1%。肌钙蛋白检测发现了更多的MACE患者,但没有显著提高风险分层的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Multisite Validation of a Strategy to Identify Very Low Risk Emergency Department Patients Without Troponin

Background

Patients with chest pain who are very low risk, defined by a History, Electrocardiogram, Age, and Risk factors (HEAR) score ≤1, may not require troponin testing.

Objectives

The aim of this study was to determine whether troponin testing is needed in patients with HEAR scores ≤1 in a multisite U.S. cohort.

Methods

We conducted an observational cohort study using the Wake Forest Chest Pain Registry. Patients ≥18 years old with HEART Pathway assessments and high-sensitivity troponin testing were accrued from 5 U.S. emergency departments (November 1, 2020-July 7, 2022). HEAR scores were prospectively completed by the treating clinician for patients with no known coronary artery disease and a nonischemic electrocardiogram. The outcome was 30-day major adverse cardiovascular events (MACE) (death, myocardial infarction [MI], and revascularization). The proportion of patients with HEAR scores ≤1 with MACE within 30 days was determined, and test characteristics were calculated. The net reclassification improvement index for troponin testing among patients with HEAR scores ≤1 was determined.

Results

Among 9,105 patients, 17.2% (1,565/9,105) had a HEAR score ≤1. At 30 days, MACE occurred in 0.7% (11/1,565; 95% CI: 0.4-1.3), with 3 deaths, 8 MIs, and 1 revascularization. The sensitivity and negative predictive value for 30-day MACE in patients with a HEAR score ≤1 were 97.9% (95% CI: 96.2-98.9) and 99.3% (95% CI: 98.7-99.6). Troponin testing correctly reclassified 8 with death, MI, or revascularization. Troponin was elevated among 74 without MACE, yielding a nonsignificant net reclassification improvement index of 0.7% (95% CI: −0.4 to 1.8).

Conclusions

Patients with no known coronary artery disease, a nonischemic electrocardiogram, and a HEAR score ≤1 had a missed MACE rate <1%. Troponin testing identified additional patients with MACE but did not significantly improve risk stratification accuracy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JACC advances
JACC advances Cardiology and Cardiovascular Medicine
CiteScore
1.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信